# National Institute of Allergy and Infectious Diseases (NIAID): Phase 1 study completed, 60 enrolled (COVID-19)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sponsor type | NIH |
| Study | Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults |
| NCT ID | NCT07183709 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | COVID-19 |
| Intervention types | biological, other |
| Target enrollment | 60 |
| Site countries | United States |
| Posted | 2025-09-19 |
| Planned start | 2026-02-02 |
| Event | Completed |
| Event date | 2026-10-21 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07183709). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.